AAPS National Biotechnology Conference 2025: AAV Vector Production
BioPharm International® sat down with Noah Kopcho, field application scientist at Gyros Protein Technologies, to talk about the challenges in the production of AAV vectors.
Adeno-associated virus (AAV) vectors are commonly used for gene therapies, according to Noah Kopcho, field application scientist at Gyros Protein Technologies. AAV vectors come with challenges in productions, however. “Namely, compared to other vectors, AAV often has lower titers,” says Kopcho. “This can present problems with scalability. During the production and purification workflow, there are several different contaminants that need to be kept in mind, and purity is often essential. And at the at the end of the workflow, you know all of these measurements that need to be made can present several different bottlenecks that that can be very time consuming and can often eat into efficiency.”
BioPharm International® sat down with Kopcho to find out how these challenges can be overcome. Click the video above to watch the interview.
Kopcho’s will be speaking on this topic at the AAPS National Biotechnology Conference 2025, which is happening May 4–7, 2025 in Boston. His presentation, “Accelerate Development of AAV-based Gene Therapies with Automated Viral Vector Titer and Impurity Analysis”, will be held on Tuesday, May 6, 2025 at 11:15 AM–12:00 PM.
About the speaker
Noah Kopcho is field application scientist at Gyros Protein Technologies.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
